A Clinical Trial of the Study Medicine (PF-07081532) in People With Diabetes and Kidney Dysfunction

Stopped early · Phase 1

Conditions studied: Type 2 Diabetes, Renal Impairment

In brief

The purpose of this study is to understand the effects of kidney functional impairment may have on the study medicine (PF-07081532). People with certain level of kidney functional impairment may process PF-07081532 differently from healthy people. PF-07081532 is developed as a potential treatment for type II diabetes. Participants will take the study medicine as a tablet by mouth once at the study clinic and then will stay at the study clinic for about 7 days. During that time, the study team will monitor their treatment experience and take some blood samples to test the level of PF-07081532. This will help us understand if certain degree of kidney functional impairment will have an effect on the study medicine PF-07081532.

Key facts

Study ID

NCT05510245

Run by

Pfizer

People needed

18

Starts

2022-08-29

Expected to finish

2023-07-20

Last updated by the study team

2024-11-05

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Stable renal function (for participants not on dialysis) defined as ≤25% difference between 2 measurements of BSA-unnormalized eGFR
• A prior diagnosis of T2DM with an HbA1c ≥6% and ≤10.5%
• Women may be of child-bearing potential
• BMI of 17.5 to 45.4 kg/m2
• NORMAL FUNCTION (GROUP 1): Normal renal function (mean eGFR ≥90 mL/min) based on an average of measures from Screening visits S1 and S2 (eGFR should be calculated using the 2021 CKD EPI Scr-Scys combined equation:
• Demographically comparable to participants with impaired renal function at Screening
• A body weight within ±15 kg of the mean body weight of the pooled renal impairment groups (Groups 2, 3 and 4)
• An age within ±10 years of the mean age of the pooled renal impairment groups (Groups 2, 3 and 4)
• Attempts will be made to ensure that the male to female distribution in Group 1 is comparable to that in the pooled renal impairment groups (Groups 2, 3 and 4).

You may not qualify if…

• Diagnosis of type 1 diabetes mellitus or secondary forms of diabetes, or history of diabetic ketoacidosis.
• History of myocardial infarction, unstable angina, arterial revascularization, stroke, New York Heart Association Functional Class II-IV heart failure, or transient ischemic attack within 3 months of Screening
• Personal or family history of MTC or MEN2, or participants with suspected MTC per the investigator's judgement.
• History of acute pancreatitis within 6 months before Screening or any history of chronic pancreatitis.
• Urinary incontinence.
• Participants with acute renal disease.
• Renal allograft recipients.
• Participants who have previously received a kidney, liver, or heart transplant.

Where it is running

• Genesis Clinical Research, LLC — Tampa, Florida, United States
• Prism Research LLC dba Nucleus Network — Saint Paul, Minnesota, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.